Synapse Electroceutical is pleased to announce that Andy Boyes has joined the Board

20-Dec-2017

Synapse Electroceutical is pleased to announce that Andy Boyes has joined the Board as an Independent Non-Executive Director.

Andy has enjoyed a successful, 32 year career at Smith & Nephew, the FTSE 100 medical technology business engaged in developing, manufacturing, marketing and selling medical devices in the Advanced Wound Management and Advanced Surgical Devices sectors with sales in excess of £4 billion. Andy is passionate about the wound care sector and helping improve the lives of patients suffering with debilitating complex wounds and since leaving Smith & Nephew has focused on providing Board level support and strategic direction in the sector.

For his last 10 years at Smith & Nephew, Andy led the Advanced Wound Management division in Europe with sales of £400 million, profit of over £100 million and a strong market leadership position, as well as leading strategic initiatives across the wider group. Prior to this he set up an Innovation group including strategic marketing, R&D, project management, clinical trials and health economics functions which led to several breakthrough developments and technology acquisitions. Andy has extensive experience of introducing innovative wound care products to the global market and successfully growing revenues for these products to over £100m. Andy brings his deep industry knowledge to Synapse at a time of change in the sector. There is significantly increased scrutiny on the cost of wound care and, consequently, on healing rates and outcomes. The major players are under pressure as the traditional products that dominate the market are commoditised and sales and margins come under significant pressure. Through years of under investment in R&D, many are starved of the type of innovation that can make compelling clinical and economic impact. The appointment of Andy to the Synapse board is a fantastic endorsement for Synapse and its technology and is sure to be noticed in the industry. 

John Gildersleeve, Synapse Electroceutical CEO said “I am delighted that Andy Boyes has agreed to join the Board. He has extensive wound care industry expertise and international experience. Andy will make an important contribution as he brings that knowledge to the development and implementation of our strategy. I very much look forward to working closely with Andy.”

Andy said of the appointment, “I am really excited to be joining Synapse Electroceutical as we share a  passion about improving the lives of patients suffering from hard to heal wounds. Over the years I have reviewed many interesting and innovative wound care products.  Accel-Heal is one of the most promising active wound care products I have appraised and I am impressed with the progress the team have made in the early stages of market introduction. I am confident that Accel-Heal has all the properties necessary to make a positive impact in the treatment of leg ulcers and I look forward to the successful commercialisation of Accel-Heal." 


Comment


No Very




Captcha Image

Go Back